We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 15 of 30 for:    cancer | First posted from 04/22/2016 to 04/22/2016

Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy (RADNET)

This study is currently recruiting participants.
Verified May 2017 by Uppsala University
Sponsor:
ClinicalTrials.gov Identifier:
NCT02749331
First Posted: April 22, 2016
Last Update Posted: May 19, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Uppsala University
  Purpose
An open-labelled, uncontrolled, single-center Phase I/IIa clinical study to evaluate the safety of repeated infusions of AdVince into the hepatic artery in patients with metastatic neuroendocrine tumors (NETs), and if possible determination of maximum tolerated dose.

Condition Intervention Phase
Neuroendocrine Tumors Drug: AdVince Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of Recombinant Adenovirus (AdVince) in Patients With Neuroendocrine Tumors; Safety and Efficacy

Resource links provided by NLM:


Further study details as provided by Uppsala University:

Primary Outcome Measures:
  • Number of Adverse Events (AE) according to Common Terminology Criteria for Adverse Events (CTCAE) v 4.03 [ Time Frame: From screening visit and through study completion, an average time of 18 months. ]
    AEs probably or possibly related to the study drug or local injuries caused by the administration procedure. If possible identify dose limiting toxicity (DLT), i.e. grade 4 toxicity of any duration or grade 3 toxicity lasting more than 7 days, excluding flu-like symptoms, according to CTCAE v4.03.Clinically significant changes in laboratory parameters (haematology, blood coagulation, liver function, biochemistry and kidney function) and vital signs (body temperature, heart rate, blood pressure, respiratory rate and consciousness according to Reaction Level Scale from 1985 (RLS-85).


Secondary Outcome Measures:
  • Change in tumor size [ Time Frame: Measured within 4 weeks before first treatment and after 80 +/-14 days (evaluation visit 1) ]
    Computer tomography (CT) and/or positron emission tomography (PET) with magnetic resonance imaging (MRI). Assessment based on Response Evaluation Criteria In Solid Tumors (RECIST) or modified RECIST (mRECIST).

  • Change in tumor size [ Time Frame: Measured within 4 weeks before first treatment and after 214 +/- 14 days (evaluation visit 2) ]
    Computer tomography (CT) and/or positron emission tomography (PET) with magnetic resonance imaging (MRI). Assessment based on Response Evaluation Criteria In Solid Tumors (RECIST) or modified RECIST (mRECIST).

  • Change in tumor metabolic activity [ Time Frame: Baseline value within 24 hrs before first treatment and after 80 +/- 14 days(evaluation visit 1) ]
    Change in hormone levels including chromogranin- A (CgA), chromogranin-B (CgB), neuron specific enolase (NSE) and specific hormones.

  • Change in tumor metabolic activity [ Time Frame: Baseline value within 24 hrs before first treatment and after 214 +/- 14 days (evaluation visit 2) ]
    Change in hormone levels including chromogranin- A (CgA), chromogranin-B (CgB), neuron specific enolase (NSE) and specific hormones.

  • Progression-free survival (PFS) [ Time Frame: Twelve weeks after 80 days from first treatment (4 treatment cycles) or the corresponding time. ]
    Number of patients with progression-free survival (PFS).

  • Change in replication profile of AdVince [ Time Frame: Before and 4hrs after each treatment cycle up to a time period of 214 days. ]
    Replication profile determined by quantification of adenovirus genomic copies in patient´s blood by quantitative real-time polymerase chain reaction (QRT-PCR).

  • Change in replication profile of AdVince [ Time Frame: Before and 24hrs after each treatment up to a time period of 214 days. ]
    Replication profile determined by quantification of adenovirus genomic copies in patient´s blood by quantitative real-time polymerase chain reaction (QRT-PCR).

  • Change in replication profile of AdVince [ Time Frame: Before and 72hrs after each treatment cycle up to a time period of 214 days. ]
    Replication profile determined by quantification of adenovirus genomic copies in patient´s blood by quantitative real-time polymerase chain reaction (QRT-PCR).

  • Change in the humoral immune response to AdVince [ Time Frame: At baseline, after 8+2 days, after 50 +/- 7days, optional after 124 +/- 7days and 184 +/- 7 days. ]
    Detection of anti-adenovirus neutralizing antibodies against adenovirus.

  • Change in the cytokine-mediated immune response [ Time Frame: At baseline and at 4hrs following each treatment up to a time period of 214 days. ]
    Measure from patient´s plasma.

  • Change in the cytokine-mediated immune response [ Time Frame: At baseline and at 24hrs following each treatment up to a time period of 214 days. ]
    Measure from patient´s plasma.

  • Change in the cytokine-mediated immune response [ Time Frame: At baseline and at 72hrs following each treatment up to a time period of 214 days. ]
    Measured from patient´s plasma.


Estimated Enrollment: 35
Study Start Date: March 2016
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: August 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AdVince

Dose escalation, minimum 3 patients per dose in Phase I. Dose levels:

  1. 10 000 000 000 virus particles
  2. 100 000 000 000 virus particles
  3. 300 000 000 000 virus particles
  4. 1000 000 000 000 virus particles

Maximum tolerated dose will be confirmed by 12 additional patients treated at this dose level in Phase IIa.

Drug: AdVince
Virus solution for infusion in intrahepatic artery
Other Name: Ad5PeptideTransductionDomain(PTD)(CgA-E1AmiR122)

Detailed Description:
An open-labelled, uncontrolled, single-center Phase I/IIa clinical study to evaluate the safety of repeated infusions of AdVince into the hepatic artery in patients with metastatic neuroendocrine tumors (NETs), and if possible determination of maximum tolerated dose. Secondary objectives include to evaluate the anti-tumoral efficacy of AdVince infusions on metastatic neuroendocrine tumors, to determine the replication profile of AdVince and to determine the humoral (antibody) and cytokine-mediated immune response to AdVince. Minimum 12 and maximum 35 patients will be included, the number is based on the toxicity observed.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject´s written informed consent
  2. Histologically and radiologically confirmed progressive neuroendocrine carcinoma of gastrointestinal, pancreatic or bronchial origin with multiple liver metastases. Progression in Clinical symptoms and tumor growth verified over the last 6 months on CT or MRI
  3. Cancer that is not considered resectable for potential cure or tumor reduction
  4. Patent portal vein and adequate liver perfusion
  5. Liver dominant disease with involvement of <60% of liver parenchyma
  6. Karnofsky performance status of >=70%
  7. Life expectancy of >=6 months
  8. >=18 years of age
  9. Must use a reliable method of contraception if sexually active and of reproductive potential
  10. Plasma creatinine <105 ug/ml
  11. Aspartate transaminase (AST), Alanine transaminase (ALT) and Alkaline Phosphatase (ALP) <3.0-fold upper limit of normal
  12. Total bilirubin <2.0-fold upper limit of normal
  13. Prothrombin time (PT)/International Normalized Ratio (INR) <2.0 and Prothromboplastin time (PTT) within normal limits
  14. Neutrophils >1500/ml, hemoglobin >100 g/L, platelets >100 000/ml
  15. Patients with functioning NET should have cover by somatostatin analog

Exclusion Criteria:

  1. Known chronic liver dysfunction Before the development of metastatic cancer (e.g. cirrhosis, chronic hepatitis)
  2. Active infection, including documented HIV and hepatitis C
  3. Any viral syndrome diagnosed within the previous 2 weeks
  4. Chemotherapy within the previous 4 weeks Before the first treatment
  5. Radiotherapy to the target tumor site within the last 24 weeks from the baseline CT scan
  6. Concomitant malignancy
  7. Pregnant or lactating females
  8. Prior participation in any research protocol that involved administration of adenovirus vectors
  9. Treatment with any other investigational therapy within the last 4 weeks, organ transplantation prior to treatment, severe cardiovascular, metabolic or pulmonary disease
  10. Continuing treatment with any other cancer therapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02749331


Contacts
Contact: Magnus Essand, Professor +46184714535 magnus.essand@igp.uu.se
Contact: Justyna Leja-Jarblad, PhD +46184714524 justyna.leja-jarblad@igp.uu.se

Locations
Sweden
Endocrine Oncology Clinic, Uppsala University Hospital Recruiting
Uppsala, Sweden, 752 37
Contact: Kjell Öberg, MD,Professor    +46186114917    kjell.oberg@akademiska.se   
Contact: Gordana Kozlovacki, MD,PhD       gordana.kozlovacki@akademiska.se   
Sponsors and Collaborators
Uppsala University
Investigators
Principal Investigator: Kjell Öberg, MD,Professor Uppsala University Hospital
  More Information

Responsible Party: Uppsala University
ClinicalTrials.gov Identifier: NCT02749331     History of Changes
Other Study ID Numbers: VIRUSNET201401
2014-000614-64 ( EudraCT Number )
First Submitted: March 11, 2016
First Posted: April 22, 2016
Last Update Posted: May 19, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Neuroendocrine Tumors
Carcinoid Tumor
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial